Kurs
+1,96%
Kurs
+1,96%
Open
229,46
High
242,08
Low
223,84
Close
239,32
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
3,55 MNOK
Likviditet
3,55 MNOK
Rel. mcap
0,98%
Antal aktier
15 213
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2026-02-19 | 13:00 | Bokslutskommuniké 2025 |
| 2025-11-19 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-21 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-20 | N/A | Årsstämma |
| 2025-02-26 | 13:00 | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-10 | - | Extra Bolagsstämma 2024 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Split BGBIO 100:1 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-22 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-15 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-29 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2022-01-06 | - | Extra Bolagsstämma 2022 |
| 2021-11-16 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2021-03-19 | - | Årsstämma |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-12-09 | - | Extra Bolagsstämma 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-17 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2020-03-16 | - | Årsstämma |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-14 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2019-03-13 | - | Årsstämma |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-15 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2018-05-14 | - | Årsstämma |
| 2018-03-09 | - | Extra Bolagsstämma 2018 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2017-03-22 | - | Årsstämma |
| 2016-06-22 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2016-06-21 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning BGBIO 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-10-01 15:20:00
Bergen, Norway, 01 October 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce that it will deliver an e
-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36[th]
Annual Meeting, taking place online from 10-14 November 2021.
Abstract titles have been announced online at the
SITC (https://www.sitcancer.org/2021/home) website. Details of the presentation
are below.
Title: AXL targeting with bemcentinb restores PD-1 blockade sensitivity
of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of
TCF1[+] CD8 T cells
Author: Rolf A. Brekken et al.
Abstract ID: 602
Full abstracts will be available on the SITC website beginning November 9th at
8:00 AM ET.
-Ends-
Contacts
Martin Olin,
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com
Rune Skeie,
Chief Financial Officer, BerGenBio ASA
rune.skeie@bergenbio.com
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a companion diagnostic test to identify patient populations most
likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com